<DOC>
	<DOCNO>NCT00176293</DOCNO>
	<brief_summary>The primary objective study assess disease response Doxil patient hormone refractory prostate cancer without dexamethasone pre-treatment . Study Design : We perform open label , parallel , randomize phase II study use two-stage design determine sufficient anti-tumor activity either arm warrant study . Assumptions make study : unacceptable overall response rate &lt; /= 10 % &amp; pursue study overall response rate &gt; /= 30 % . Fifteen patient randomize first phase ( Arm 1 Arm 2 ) . No patient accrue &lt; 2/15 response note give arm . Ten additional patient enrol &gt; /= 2/15 response observe . If &gt; /= 5/25 response study pursue regimen . We determine overall incidence &amp; severity toxicity arm . Treatment : Arm 1 : Doxil : Dose : 50 mg/m2 , IV ( vein ) day 5 28 day cycle . Arm 2 : Doxil : Dose : 50 mg/m2 , IV ( vein ) day 5 28 day cycle . Arm 1 : Dexamethasone : Dose : 12 mg twice day mouth day 1 , 2 , 3 , 4 , 5 28 day cycle . Number Cycles Arm 1 &amp; 2 : progression unacceptable toxicity develop .</brief_summary>
	<brief_title>Randomized Phase II Trial Doxil With Without Dexamethasone Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>Primary Objectives : To assess anti-tumor activity Doxil assess response rate patient hormone refractory prostate cancer without dexamethasone pre-treatment . Secondary Objectives : To assess estimate patient hormone refractory prostate cancer treat Doxil without pre-treatment dexamethasone : 1 ) overall survival 2 ) toxicity , 3 ) quality life parameter , 4 ) dose intensity administer treatment group . Study Design : We perform open label , parallel , randomize phase II study use two-stage design determine sufficient anti-tumor activity either arm warrant study . Assumptions make study : unacceptable overall response rate &lt; /= 10 % pursue study overall response rate &gt; /= 30 % . The overall response rate study base total number response observe defined : complete response + partial response ( RECIST ) +biochemical response ( patient measurable target lesion &gt; /= 50 % decrease PSA &gt; /= 4 week ) . Fifteen patient randomize first phase ( Arm 1 Arm 2 ) . No patient accrue &lt; 2/15 response note give arm . Ten additional patient enrol &gt; /= 2/15 response observe . If &gt; /= 5/25 response study pursue regimen . We determine overall incidence severity toxicity arm . Treatment : Arm 1 : Doxil : Dose : 50 mg/m2 , IV . Frequency : day 5 28 day cycle . Arm 2 : Doxil : Dose : 50 mg/m2 , IV . Frequency : day 5 28 day cycle . Arm 1 : Dexamethasone : Dose : 12 mg bid po . Frequency : day 1,2,3,4,5 28 day cycle . Number Cycles Arm 1 2 : progression unacceptable toxicity develop .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients metastatic hormone refractory prostate cancer define resistance ablative therapy ( either LHRH agonists orchiectomy ) &amp; antiandrogens . 2 . Patients must symptoms related disease . 3 . Patients must PS 0,1,2 ( ECOG ) . 4 . Patients must measurable disease ( RECIST ) PSA &gt; 5 . 5 . Patients must adequate organ function define follow : leukocyte &gt; /= 3,000/mm3 , absolute neutrophil count &gt; /= 1,500/mm3 , hemoglobin &gt; /= 8.0g/dl , platelet &gt; /= 100,000/mm3 , serum creatinine &lt; /= 2.5 mg/dl . Bilirubin must &lt; /= 2 fold ULN . Liver transaminases ( SGOT and/or SGPT ) may 2.5 x institutional ULN alkaline phosphatase &lt; /= ULN alkaline phosphatase may 4 x ULN transaminases &lt; /= ULN . 6 . Patients must leave ventricular ejection fraction ( LVEF ) 50 % echocardiogram 7 . Patients must fail respond discontinuation antiandrogens . 8 . No previous therapy antiandrogens , corticosteroid estrogens last 4 week . 9 . Previous radiation therapy allow complete least 4 week prior study entry &amp; therapy cumulatively administer &lt; /= 25 % bone marrow . 10 . Patients must &gt; 18 year age 11 . Patients must expect survival least 4 month . 12 . Patients must ability understand &amp; willingness sign write informed consent document . 13 . Patients must willing use adequate contraceptive method treatment 3 month complete treatment . 1 . Patients previous history cancer exclude unless curative treatment complete &gt; /= 5 year prior entry onto study 1 following : situ carcinoma ( location ) , basal cell carcinoma , nonmetastatic squamous cell carcinoma skin . 2 . Uncontrolled intercurrent illness include , limited ongoing active infection , uncontrolled diabetes mellitus , psychiatric illness/social situation would limit compliance study requirement ability provide inform consent . 3 . Patients require non study corticosteroid reason exclude . 4 . Patients receive previous chemotherapy . 5 . A history cardiac disease New York Heart Class II great , clinical evidence congestive heart failure . 6 . Patients may receive investigational agent participate investigational drug study within 4 week precede initiation treatment . 7 . Major surgery within 4 week prior study treatment start , lack complete recovery major surgery . 8 . Patients lack physical integrity upper gastrointestinal tract malabsorption syndrome inability swallow tablet . 9 . History hypersensitivity reaction attribute conventional formulation doxorubicin HCL component DoxilÂ®</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>prostate</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>doxil</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>metastatic</keyword>
	<keyword>hormone refractory</keyword>
</DOC>